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Introduction
Regulatory T cells (Treg) are crucial for maintaining
immune homeostasis and mediating immune tolerance.
Several studies have shown that Treg can produce cyto-
kines. CD161, a C-type lectin receptor, identifies Treg
that produce cytokines. Interestingly, CD161+ Treg are
enriched in the inflamed joint of Juvenile Idiopathic
Arthritis (JIA) patients and their numbers relate to clini-
cal disease severity suggesting that CD161+ Treg may
play an important role in disease pathogenesis. If Treg
are to be used as a cell therapy it may be important to
define ways to prevent cytokine production from these
cells in vivo.
Objectives
To analyse and define the transcriptional and protein
signatures of CD161+ Treg compared to CD161- Treg.
Methods
CD161+ and CD161- Treg were isolated from blood of
healthy controls using FACS sorting. Transcriptional dif-
ferences were analysed using RNA sequence and protein
signature by flow cytometry.
Results
Analysis of transcriptional differences between CD161+
and CD161- Treg highlighted many interesting differen-
tially expressed genes, including Treg-specific genes and
genes associated with memory phenotype. RNA and pro-
tein expression correlate well for the genes and proteins
examined. Pathway analysis of differentially expressed
genes indicates the importance of several pathways. For
example, epithelial adherence junction signalling, T helper
cell differentiation, cell cycle and STAT3 pathway. Future
work will focus on exploring the biological importance of
these pathways in CD161+ and CD161- Treg in both
healthy individuals and JIA patients.
Conclusion
Analysis of transcriptional differences and protein signa-
ture of CD161+ and CD161- Treg cells indicates that
these two Treg subpopulations have a different phenotype
and may have arisen via different pathways. The genera-
tion of a large novel data set concerning transcriptional
signatures of CD161+ and CD161- Treg has yielded a rich
source of pathways and mechanisms that warrant further
investigation and may generate novel targets for drug
development.
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